Article
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
Journal of cancer research and clinical oncology - 1 Oct 2022
Wei Hao, Zhou Xiaojuan, Yang Hui, Gong Youling, Wang Jin, Xu Yong, Zhou Lin, Xue Jianxin, Zou Bingwen, Zhang Yan, Zhu Jiang, Peng Feng, Huang Meijuan, Lu You, Liu Yongmei
Abstract excerpt
PURPOSE: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. METHODS: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All selected patients were treated with first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.